ПОРІВНЯННЯ 2DІ 3D ПЕРВИННОЇ КУЛЬТУРИ КЛІТИН, ОТРИМАНОЇ З ЕКСПЛАНТАТА НИЗЬКОДИФЕРЕНЦІЙОВАНОГО УРОТЕЛІАЛЬНОГО РАКУ СЕЧОВОГО МІХУРА
Studying the biological characteristics of bladder cancer in primary culture can be an effective way for diagnostic and prognostic purposes, as well as choosing a scheme for personalized therapy. Aim: To characterize and compare 2D and 3D primary cell cultures obtained from the same tumor sample res...
Збережено в:
| Дата: | 2023 |
|---|---|
| Автори: | , , , , , , |
| Формат: | Стаття |
| Мова: | English |
| Опубліковано: |
PH Akademperiodyka
2023
|
| Теми: | |
| Онлайн доступ: | https://exp-oncology.com.ua/index.php/Exp/article/view/2023-1-14 |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
| Назва журналу: | Experimental Oncology |
Репозитарії
Experimental Oncology| Резюме: | Studying the biological characteristics of bladder cancer in primary culture can be an effective way for diagnostic and prognostic purposes, as well as choosing a scheme for personalized therapy. Aim: To characterize and compare 2D and 3D primary cell cultures obtained from the same tumor sample resected from a patient with high-grade bladder cancer. Materials and Methods: 2D and 3D primary cell cultures were obtained from explants of resected bladder cancer. Glucose metabolism, lactate dehydrogenase (LDH) activity, and level of apoptosis were studied. Results: Multicellular tumor spheroids (3D) differ from planar culture (2D) by more pronounced consumption of glucose from the culture medium (1.7 times higher than 2D on Day 3 of culture), increased lactate dehydrogenase activity (2.5 times higher on Day 3 vs. Day 1 of cultivation, while in 2D culture LDH activity is constant), stronger acidification of the extracellular environment (pH dropped by 1 in 3D and by 0.5 in 2D). Spheroids demonstrate enhanced resistance to apoptosis (1.4 times higher). Conclusion: This methodological technique can be used both for tumor characterization and for selection of optimal postoperative chemotherapeutic schemes. |
|---|